You are here
Cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.
General Session 1: Risk-Based Health Care of Cancer Survivors in the 21st Century
Background: Few studies have systematically evaluated CBM in survivors of adult-onset cancer, accounting for both the number and severity of health conditions (HCs). TCS provide a unique opportunity to do this, given their young age at diagnosis, relatively homogeneous cisplatin-based chemotherapy (CHEM) and high cure rates. We comprehensively evaluated CBM after CHEM among TCS enrolled in an ongoing multi-center investigation (the Platinum Study). Methods: Eligible TCS (aged < 50 y at diagnosis and given first line CHEM) completed questionnaires assessing a comprehensive panel of HCs and prescription drug use. HCs (n = 54) were mapped and graded to the NCI Common Terminology Criteria for Adverse Events v4.03. A CBM score was calculated based on number and severity of each HC, following Geenen et al. (JAMA 2007; 297:2705). To examine the association between CBM score and both health status and cumulative cisplatin dose, we applied ordinal logistic regression adjusting for age at evaluation and bleomycin use. Results: Among the first 751 consecutively enrolled TCS, median age at evaluation was 38 y and median time since CHEM 4.6 y (range, 1-30 y). The most common HCs were paresthesias (27% grade 1, 18% grade 2, 17% grade 3), hearing loss (27% grade 1, 15% grade 1, 1.3% grade 3, 0.1% grade 4), tinnitus (31% grade 1, 7% grade 2, 7% grade 3), and obesity (42% grade 2, 29% grade 3, 4% grade 4. Low, medium, high, and severe CBM scores were observed in 8%, 69%, 20%, and 0.5% TCS, respectively, with a score of zero in 3%. Increasing CBM score was significantly associated with worse self-reported health status (OR = 2.34, 95% CI 1.91, 2.87; p < 0.001). Each 100 mg/m2 increase in cisplatin dose was associated with a non-significant increase in CBM (OR per 100 mg/m2 = 1.14; 95% CI, 0.96-1.34; p = 0.129). Adjustment for bleomycin did not affect results. CBM score increased with older age at evaluation (p < 0.001). Conclusions: CBM is strongly correlated with worse self-reported health, indicating that HCs frequently seen after CHEM are perceived by TCS as impacting negatively on their health. Survivorship care plans for TCS should take into account the CBM which appears relatively early, and is likely to increase with the aging of this population.
Abstracts by Sarah L Kerns:
Presentations by Sarah L Kerns:
Meeting: 2016 Cancer Survivorship Symposium
Abstract No: 106
Session: General Session 1: Risk-Based Health Care of Cancer Survivors in the 21st Century (General Session)